Company Description
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.
The company’s diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations.
It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.
The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H.
Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria.
Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1971 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Zackary Irani |
Contact Details
Address: 17571 Von Karman Avenue Irvine, California 92614 United States | |
| Phone | 949 645 2111 |
| Website | biomerica.com |
Stock Details
| Ticker Symbol | BMRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0000073290 |
| CUSIP Number | 09061H406 |
| ISIN Number | US09061H4065 |
| Employer ID | 95-2645573 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Zackary S. Irani | Chief Executive Officer and Director |
| Allen C. Barbieri | Executive Vice-Chairman of the Board and Corporate Secretary |
| Gary Lu CPA | Principal Accounting Officer and Chief Financial Officer |
| Lucy Liu Ph.D. | Director of Manufacturing and Technical Operations |
| Scott Madel | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 20, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 14, 2025 | 10-Q | Quarterly Report |
| Oct 9, 2025 | PRE 14A | Other preliminary proxy statements |
| Oct 8, 2025 | 8-K | Current Report |
| Sep 26, 2025 | 10-K/A | [Amend] Annual report |
| Aug 29, 2025 | 10-K | Annual Report |
| Jun 6, 2025 | 8-K | Current Report |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 14, 2025 | 10-Q | Quarterly Report |